FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Vet Intern Med / Minimum inhibitory concentrations of equine Corynebacterium ...
Journal of veterinary internal medicine2015; 29(1); 327-332; doi: 10.1111/jvim.12534

Minimum inhibitory concentrations of equine Corynebacterium pseudotuberculosis isolates (1996-2012).

Abstract: Few studies report the minimum inhibitory concentrations for antimicrobials against equine Corynebacterium pseudotuberculosis isolates. Objective: To evaluate trends in the in vitro activities of 20 antimicrobials against equine Corynebacterium pseudotuberculosis isolates from 1996 to 2012 and to determine if a relationship exists between the minimum inhibitory concentration (MIC) and location of the abscess. Methods: Corynebacterium pseudotuberculosis isolates from 196 horses with naturally occurring disease. Methods: Retrospective and cross-sectional design. Medical records were reviewed to obtain clinical and MIC data. Minimum inhibitory concentrations were determined by the microdilution technique. The MIC results over 3 periods were compared (1996-2001, 2002-2006, 2007-2012). Results: The MIC90 values for clinically relevant antimicrobials were as follows: chloramphenicol ≤ 4 μg/mL, enrofloxacin ≤ 0.25 μg/mL, gentamicin ≤ 1 μg/mL, penicillin =0.25 μg/mL, rifampin ≤ 1 μg/mL, tetracycline ≤ 2 μg/mL, trimethoprim-sulfamethoxazole (TMS) ≤ 0.5 μg/mL, ceftiofur =2 μg/mL, and doxycycline ≤ 2 μg/mL. There were no significant changes in MIC results over the study period. There was no relationship between MIC patterns and abscess location. Conclusions: The MIC50 and MIC90 values of antimicrobials evaluated in this study for equine isolates of C. pseudotuberculosis did not vary over time. Abscess location was not associated with different MIC patterns in cultured isolates. Several commonly used antimicrobials are active in vitro against C. pseudotuberculosis in vitro.
Copyright © 2015 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of American College of Veterinary Internal Medicine.
Get Full Text
Publication Date: 2015-01-14 PubMed ID: 25586790PubMed Central: PMC4858058DOI: 10.1111/jvim.12534Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research investigates the effectiveness of 20 antimicrobial drugs on equine Corynebacterium pseudotuberculosis infections collected from 1996 to 2012. In particular, it analyzes statistical trends to find any relationship between the abscess location and the minimum drug concentrations needed for bacterial growth inhibition (MIC). The conclusion demonstrates that most antimicrobials maintain their efficiency over time, and there is no significant relationship between the MIC patterns and the location of the abscess.

Objective and Methodology

  • In this study, the researchers aim to examine trends in antimicrobial efficiencies against equine Corynebacterium pseudotuberculosis infections from 1996-2012. Additionally, they aim to derive any patterns between the necessary minimum inhibitory concentrations (MIC) and abscess location.
  • The investigators collected isolates from 196 horses naturally suffering from the disease. The study followed a retrospective and cross-sectional design, wherein former medical records were accessed for information on clinical and MIC data.
  • The MIC was assessed using the microdilution technique, a common way of determining the smallest amount of drug necessary to inhibit bacterial growth.
  • For a better understanding and accurate analysis of trends, the research was divided into three phases: 1996-2001, 2002-2006, and 2007-2012.

Results

  • Notable clinically relevant antimicrobials and their MIC90 values are presented. MIC90 represents the minimum concentration of the antimicrobial that inhibits 90% of a bacterial population. These values suggest the relative potency of the drugs against the bacterial infections.
  • The study found no significant changes in MIC results throughout the period from 1996 to 2012, suggesting that the efficiency of these antimicrobials remained constant over time.
  • No correlation was found between MIC patterns and abscess location, indicating that the pathogen presents the same level of susceptibility to the drugs regardless of where the infection is present in the body.

Conclusions

  • The consistent MIC50 and MIC90 values of the antibacterial drugs against Corynebacterium pseudotuberculosis suggest the unchanging potency of these antimicrobials over time.
  • Abscess location does not influence the effectiveness of the antimicrobials, as evidenced by the unvarying MIC patterns.
  • The in vitro activities of many commonly used antimicrobials remained effective against C. pseudotuberculosis throughout the study period, offering useful insights into infection management in horses.

Cite This Article

APA
Rhodes DM, Magdesian KG, Byrne BA, Kass PH, Edman J, Spier SJ. (2015). Minimum inhibitory concentrations of equine Corynebacterium pseudotuberculosis isolates (1996-2012). J Vet Intern Med, 29(1), 327-332. https://doi.org/10.1111/jvim.12534

Publication

Journal of veterinary internal medicine
ISSN: 1939-1676
NlmUniqueID: 8708660
Country: United States
Language: English
Volume: 29
Issue: 1
Pages: 327-332

Researcher Affiliations

Rhodes, D M
  • School of Veterinary Medicine, W.R. Pritchard Veterinary Medical Teaching Hospital, University of California, Davis, CA.
Magdesian, K G
    Byrne, B A
      Kass, P H
        Edman, J
          Spier, S J

            MeSH Terms

            • Abscess / drug therapy
            • Abscess / microbiology
            • Abscess / veterinary
            • Animals
            • Anti-Bacterial Agents / pharmacology
            • Corynebacterium Infections / microbiology
            • Corynebacterium Infections / veterinary
            • Corynebacterium pseudotuberculosis / drug effects
            • Drug Resistance, Bacterial
            • Female
            • Horse Diseases / microbiology
            • Horses
            • Male
            • Microbial Sensitivity Tests
            • Retrospective Studies
            • Time Factors

            References

            This article includes 34 references
            1. Costa LR, Spier SJ, Hirsh DC. Comparative molecular characterization of Corynebacterium pseudotuberculosis of different origin.. Vet Microbiol 1998 May;62(2):135-43.
              pubmed: 9695286doi: 10.1016/s0378-1135(98)00202-8google scholar: lookup
            2. Poonacha KB, Donahue JM. Abortion in a mare associated with Corynebacterium pseudotuberculosis infection.. J Vet Diagn Invest 1995 Oct;7(4):563-4.
              pubmed: 8580187doi: 10.1177/104063879500700428google scholar: lookup
            3. Perkins SL, Magdesian KG, Thomas WP, Spier SJ. Pericarditis and pleuritis caused by Corynebacterium pseudotuberculosis in a horse.. J Am Vet Med Assoc 2004 Apr 1;224(7):1133-8, 1112.
              pubmed: 15074860doi: 10.2460/javma.2004.224.1133google scholar: lookup
            4. Farstvedt EG, Hendrickson DA, Dickenson CE, Spier SJ. Treatment of suppurative facial cellulitis and panniculitis caused by Corynebacterium pseudotuberculosis in two horses.. J Am Vet Med Assoc 2004 Apr 1;224(7):1139-42, 1112.
              pubmed: 15074861doi: 10.2460/javma.2004.224.1139google scholar: lookup
            5. Pratt SM, Spier SJ, Carroll SP, Vaughan B, Whitcomb MB, Wilson WD. Evaluation of clinical characteristics, diagnostic test results, and outcome in horses with internal infection caused by Corynebacterium pseudotuberculosis: 30 cases (1995-2003).. J Am Vet Med Assoc 2005 Aug 1;227(3):441-8.
              pubmed: 16121612doi: 10.2460/javma.2005.227.441google scholar: lookup
            6. Aleman M, Spier SJ, Wilson WD, Doherr M. Corynebacterium pseudotuberculosis infection in horses: 538 cases (1982-1993).. J Am Vet Med Assoc 1996 Aug 15;209(4):804-9.
              pubmed: 8756884
            7. Papich MG. Current concepts in antimicrobial therapy for horses.. Proc Ann Conv AAEP 2001;47:94–102.
            8. Judson R, Songer JG. Corynebacterium pseudotuberculosis: in vitro susceptibility to 39 antimicrobial agents.. Vet Microbiol 1991 Apr;27(2):145-50.
              pubmed: 2063546doi: 10.1016/0378-1135(91)90005-zgoogle scholar: lookup
            9. Burton AJ, Giguère S, Sturgill TL, Berghaus LJ, Slovis NM, Whitman JL, Levering C, Kuskie KR, Cohen ND. Macrolide- and rifampin-resistant Rhodococcus equi on a horse breeding farm, Kentucky, USA.. Emerg Infect Dis 2013 Feb;19(2):282-5.
              pmc: PMC3559061pubmed: 23347878doi: 10.3201/eid1902.121210google scholar: lookup
            10. Carlson KL, Kuskie KR, Chaffin KM, Libal MC, Giguère S, Lawhon SD, Cohen ND. Antimicrobial activity of tulathromycin and 14 other antimicrobials against virulent Rhodococcus equi in vitro.. Vet Ther 2010 Summer;11(2):E1-9.
              pubmed: 20957614
            11. Hinic V, Lang C, Weisser M, Straub C, Frei R, Goldenberger D. Corynebacterium tuberculostearicum: a potentially misidentified and multiresistant Corynebacterium species isolated from clinical specimens.. J Clin Microbiol 2012 Aug;50(8):2561-7.
              pmc: PMC3421492pubmed: 22593594doi: 10.1128/jcm.00386-12google scholar: lookup
            12. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; approved standard‐3rd edition.. CLSI Document M31‐A3 2008;28:65–72.
            13. Clinical and Laboratory Standards Institute. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; approved guideline‐2nd edition.. CLSI Document M45‐A2 2010;30:18–19.
            14. Giguère S, Lee E, Williams E, Cohen ND, Chaffin MK, Halbert N, Martens RJ, Franklin RP, Clark CC, Slovis NM. Determination of the prevalence of antimicrobial resistance to macrolide antimicrobials or rifampin in Rhodococcus equi isolates and treatment outcome in foals infected with antimicrobial-resistant isolates of R equi.. J Am Vet Med Assoc 2010 Jul 1;237(1):74-81.
              pubmed: 20590498doi: 10.2460/javma.237.1.74google scholar: lookup
            15. Gustafsson A, Båverud V, Gunnarsson A, Rantzien MH, Lindholm A, Franklin A. The association of erythromycin ethylsuccinate with acute colitis in horses in Sweden.. Equine Vet J 1997 Jul;29(4):314-8.
              pubmed: 15338913doi: 10.1111/j.2042-3306.1997.tb03129.xgoogle scholar: lookup
            16. Adamson PJ, Wilson WD, Hirsh DC, Baggot JD, Martin LD. Susceptibility of equine bacterial isolates to antimicrobial agents.. Am J Vet Res 1985 Feb;46(2):447-50.
              pubmed: 3994111
            17. Uboh CE, Soma LR, Luo Y, McNamara E, Fennell MA, May L, Teleis DC, Rudy JA, Watson AO. Pharmacokinetics of penicillin G procaine versus penicillin G potassium and procaine hydrochloride in horses.. Am J Vet Res 2000 Jul;61(7):811-5.
              pubmed: 10895905doi: 10.2460/ajvr.2000.61.811google scholar: lookup
            18. Winther L, Honoré Hansen S, Baptiste KE, Friis C. Antimicrobial disposition in pulmonary epithelial lining fluid of horses, part II. Doxycycline.. J Vet Pharmacol Ther 2011 Jun;34(3):285-9.
              pubmed: 20950348doi: 10.1111/j.1365-2885.2010.01229.xgoogle scholar: lookup
            19. Papich MG, Davis JL. Antimicrobial therapy. Equine Infectious Diseases 2007:578–591.
            20. Haines GR, Brown MP, Gronwall RR, Merritt KA. Serum concentrations and pharmacokinetics of enrofloxacin after intravenous and intragastric administration to mares.. Can J Vet Res 2000 Jul;64(3):171-7.
              pmc: PMC1189609pubmed: 10935883
            21. Epstein K, Cohen N, Boothe D, Nieuwoudt C, Chandler J. Pharmacokinetics, stability, and retrospective analysis of use of an oral gel formulation of the bovine injectable enrofloxacin in horses.. Vet Ther 2004 Summer;5(2):155-67.
              pubmed: 15468012
            22. Ohki E, Yamagishi Y, Mikamo H. Relationship between the clinical efficacy and AUC/MIC of intravenous ciprofloxacin in Japanese patients with intraabdominal infections.. J Infect Chemother 2013 Oct;19(5):951-5.
              pubmed: 23322394doi: 10.1007/s10156-012-0512-6google scholar: lookup
            23. Brown MP, Gronwall R, Castro L. Pharmacokinetics and body fluid and endometrial concentrations of trimethoprim-sulfamethoxazole in mares.. Am J Vet Res 1988 Jun;49(6):918-22.
              pubmed: 3261143
            24. Gustafsson A, Båverud V, Franklin A, Gunnarsson A, Ogren G, Ingvast-Larsson C. Repeated administration of trimethoprim/sulfadiazine in the horse--pharmacokinetics, plasma protein binding and influence on the intestinal microflora.. J Vet Pharmacol Ther 1999 Feb;22(1):20-6.
              pubmed: 10211713doi: 10.1046/j.1365-2885.1999.00183.xgoogle scholar: lookup
            25. van der Harst MR, Bull S, Laffont CM, Klein WR. Influence of fluid therapy on gentamicin pharmacokinetics in colic horses.. Vet Res Commun 2005 Feb;29(2):141-7.
              pubmed: 15730138doi: 10.1023/b:verc.0000047493.50112.97google scholar: lookup
            26. Magdesian KG, Hogan PM, Cohen ND, Brumbaugh GW, Bernard WV. Pharmacokinetics of a high dose of gentamicin administered intravenously or intramuscularly to horses.. J Am Vet Med Assoc 1998 Oct 1;213(7):1007-11.
              pubmed: 9776999
            27. Dowling PM. Aminoglycosides. Antimicrobial Therapy in Veterinary Medicine 2006:207–229.
            28. Pinto N, Schumacher J, Taintor J, Degraves F, Duran S, Boothe D. Pharmacokinetics of amikacin in plasma and selected body fluids of healthy horses after a single intravenous dose.. Equine Vet J 2011 Jan;43(1):112-6.
              pubmed: 21143642doi: 10.1111/j.2042-3306.2010.00144.xgoogle scholar: lookup
            29. Gronwall R, Brown MP, Merritt AM, Stone HW. Body fluid concentrations and pharmacokinetics of chloramphenicol given to mares intravenously or by repeated gavage.. Am J Vet Res 1986 Dec;47(12):2591-5.
              pubmed: 3800117
            30. Cox S, Sommardahl C, McElligott E. Pharmacokinetics of oral chloramphenicol base in adult horses at 50 mg/kg dosage.. Abstracts ACVIM Forum 2014.
            31. Wilson WD, Spensley MS, Baggot JD, Hietala SK. Pharmacokinetics, bioavailability, and in vitro antibacterial activity of rifampin in the horse.. Am J Vet Res 1988 Dec;49(12):2041-6.
              pubmed: 3239839
            32. Liu Y, Cui J, Wang R, Wang X, Drlica K, Zhao X. Selection of rifampicin-resistant Staphylococcus aureus during tuberculosis therapy: concurrent bacterial eradication and acquisition of resistance.. J Antimicrob Chemother 2005 Dec;56(6):1172-5.
              pubmed: 16207765doi: 10.1093/jac/dki364google scholar: lookup
            33. Walker R. Antimicrobial susceptiblity testing methods and interpretation of results. Antimicrobial Therapy in Veterinary Medicine 2006:11–25.
            34. Muckle CA, Gyles CL. Characterization of strains of corynebacterium pseudotuberculosis.. Can J Comp Med 1982 Apr;46(2):206-8.
              pmc: PMC1320282pubmed: 7093813

            Citations

            This article has been cited 7 times.
            1. Meng W, Chen S, Huang L, Yang J, Zhang W, Zhong Z, Zhou Z, Liu H, Fu H, He T, Peng G. Isolation, characterization, and pathogenicity assessment of Corynebacterium pseudotuberculosis biovar equi strains from alpacas (Vicugna pacos) in China.. Front Microbiol 2023;14:1206187.
              doi: 10.3389/fmicb.2023.1206187pubmed: 37465023google scholar: lookup
            2. Stanisic D, Fregonesi NL, Barros CHN, Pontes JGM, Fulaz S, Menezes UJ, Nicoleti JL, Castro TLP, Seyffert N, Azevedo V, Durán N, Portela RW, Tasic L. NMR insights on nano silver post-surgical treatment of superficial caseous lymphadenitis in small ruminants.. RSC Adv 2018 Dec 4;8(71):40778-40786.
              doi: 10.1039/c8ra08218apubmed: 35557902google scholar: lookup
            3. Santos LM, Rodrigues DM, Kalil MA, Azevedo V, Meyer R, Umsza-Guez MA, Machado BA, Seyffert N, Portela RW. Activity of Ethanolic and Supercritical Propolis Extracts in Corynebacterium pseudotuberculosis and Its Associated Biofilm.. Front Vet Sci 2021;8:700030.
              doi: 10.3389/fvets.2021.700030pubmed: 34540932google scholar: lookup
            4. Pye J, Galuppo L, Whitcomb MB, Clothier K, Byrne B. Isolation of Campylobacter fetus subspecies fetus from an abdominal abscess in an adult mare.. Can Vet J 2020 Dec;61(12):1307-1311.
              pubmed: 33299249
            5. Baraúna RA, Ramos RT, Veras AA, Pinheiro KC, Benevides LJ, Viana MV, Guimarães LC, Edman JM, Spier SJ, Azevedo V, Silva A. Assessing the Genotypic Differences between Strains of Corynebacterium pseudotuberculosis biovar equi through Comparative Genomics.. PLoS One 2017;12(1):e0170676.
              doi: 10.1371/journal.pone.0170676pubmed: 28125655google scholar: lookup
            6. Corbeil LE, Morrissey JF, Léguillette R. Is Corynebacterium pseudotuberculosis infection (pigeon fever) in horses an emerging disease in western Canada?. Can Vet J 2016 Oct;57(10):1062-1066.
              pubmed: 27708444
            7. Toombs-Ruane LJ, Riley CB, Kendall AT, Bolwell CF, Benschop J, Rosanowski SM. Antimicrobial Susceptibilities of Aerobic Isolates from Respiratory Samples of Young New Zealand Horses.. J Vet Intern Med 2015 Nov-Dec;29(6):1700-6.
              doi: 10.1111/jvim.13600pubmed: 26289293google scholar: lookup
            Subscribe to our newsletter
            Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.